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Case presentation
A 65-year-old white man with long-standing ischemic cardiomyo-
pathy and congestive heart failure was hospitalized because of 2 weeks
of increasing dyspnea at rest, weight gain, and the onset of rapid atrial
fibrillation.
Fifteen years earlier, the patient had an acute myocardial infarction
complicated by congestive heart failure; digoxin and thiazide diuretics
were prescribed. Over the ensuing years, he had progressive angina and
required diagnostic cardiac catheterization, which revealed three-vessel
disease. The patient had undergone coronary artery bypass surgery 3
years earlier. The postoperative course was complicated by a "post-
cardiotomy syndrome." A postoperative echocardiogram showed per-
sistent left ventricular enlargement with marked dysfunction. Over the
next year, the patient noted 6-pillow orthopnea, nocturia, and
exertional dyspnea of 4 to 5 steps. Blood pressure was 170/100mm Hg
and serum creatinine was 1.8 mg/dl. Methyldopa, 500 mg four times
daily, and later hydralazine, 25 mg orally twice daily, were added to the
patient's regimen. Ibuprofen was given intermittently for chest wall
pain. Eventually hydrochlorothiazide administration was discontinued
and furosemide was prescribed in a dose of 40 mg/day.
Two years before the current admission, the patient was admitted to
the hospital for worsening congestive heart failure. Furosemide was
increased to 80 mg daily, and captopril, 50 mg three times a day, was
added. Methyldopa and hydralazine were discontinued. Over the next
22 months, the patient was admitted to the hospital five times for
management of increasing congestive heart failure. Serum creatinine
increased gradually to 4.3 mg/dl while he was receiving captopril and
returned to 2 mgldl when captopril was stopped. Medications 2 months
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prior to the current admission included diltiazem, furosemide, long-
acting nitrates, prazosin, and metolazone.
Examination at the time of admission revealed a dyspneic white male
with a protuberant abdomen who was lying in bed at an angle of 40°.
The respiratory rate was 25/mm. Blood pressure was 125/75 mm Hg
supine and 112/75 mm Hg sitting. Pertinent physical findings includedjugular venous pressure of 11 cm with hepatojugular reflux. Cardiac
examination revealed a dyskinetic and diffuse apical impulse displaced
laterally to the anterior axillary line; SI and S2 were audible, and a Il/VI
holosystolic murmur was heard at the apex radiating to the axilla.
Bilateral inspiratory rales were evident at both lung bases. He had a
distended abdomen with shifting dullness and a fluid wave. The liver
span was 10 cm by percussion; the edge was not palpable. No
splenomegaly was present. Bowel sounds were normal. Pulses were 2 +
throughout without bruits. There was bilateral 1 + pedal edema. The
neurologic examination was essentially normal.
Admission laboratory data included: serum sodium, 129 mEq/liter;
potassium, 3.9 mEq/liter; chloride, 88 mEq/Iiter; and bicarbonate, 27
mEq/liter. The BUN was 60 mg/dl and the serum creatinine 3.2 mg/dl.
Calcium was 6.3 mg/dl; phosphate, 4.3 mgldl; and glucose, 88 mg/dl.
The alkaline phosphatase was 134 units; LDH, 263 units; and SGOT, 41
units. Total bilirubin was 0.5 mg/dl; albumin, 2.4 g/dl; and uric acid, 11
mg/dl. Urinalysis showed 1 + protein as well as 0 to 1 white blood cells,
0 to 1 red blood cells, and a few hyaline casts/high-power field. Arterial
blood gases at room air revealed a P02 of 36 mm Hg; pH, 7.5; and 97%
02 saturation. An electrocardiogram disclosed atrial fibrillation with a
ventricular response of approximately 150/mm, axis of -20°, and Q
waves in V 1-4 with poor R-wave progression consistent with an
anteroseptal myocardial infarction of indeterminate age; lateral ST- and
T-wave abnormalities were consistent with strain, ischemia, or the
effect of digitalis. Chest x-ray showed cardiomegaly, pulmonary vascu-
lar redistribution, and a blunted left costophrenic angle.
Intravenous furosemide (up to 200 mg per dose) produced only a mild
diuresis. Quinidine was given for atrial fibrillation, and the patient
eventually underwent electrical cardioversion. Normal sinus rhythm
was achieved, but he continued to complain of anorexia, fatigue, and
shortness of breath. Concomitantly, the BUN and serum creatinine
rose to 80 and 4.5 mg/dl, respectively. Urine output remained at
approximately 1400 cc/day. Urinalysis continued to reveal trace pro-
tein, hyaline casts, and 0 to 1 white blood cells per/high-power field. A
Swan-Ganz catheter was inserted. Initial pulmonary capillary wedge
pressure was 20 mm Hg, cardiac index was 1.6 liters/min/l .73 m2, and
the calculated systemic vascular resistance was approximately 2000
dynes sec1 cm5. Dobutamine administration increased the cardiac
index to 2.2 liters/min/l.73 m2 and decreased the systemic vascular
resistance to 1600 dynes sec cm5. Dobutamine was stopped, and
low-dose dopamine and increasing doses of sodium nitroprusside were
given. However, the patient developed transient marked oliguria (<10
cc/hr) while the blood pressure hovered at 90/60 mm Hg. Dopamine and
nitroprusside administration were halted. Captopril was tried, but
oliguria persisted despite a transient increase in the cardiac index.
A renal arteriogram was performed to evaluate the possibility of
bilateral renal artery stenosis and correctable lesions. Renal angiogram
revealed right renal artery occlusion and left renal artery ostial stenosis;
angioplasty with a 6 mm balloon dilated the left stenosis successfully.
Immediately after dilation, dobutamine and nitroprusside were given,
and the patient responded to intravenous furosemide with a remarkable
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diuresis. Dobutamine and nitroprusside were discontinued gradually,
and oral captopril was prescribed. In addition to a 4 kg diuresis with
symptomatic improvement, the patient's BUN and serum creatinine fell
to 37.0 and 2.0 mg/dl respectively. At discharge the blood pressure was
105—125/60—75 mm Hg. Discharge medications were captopril, 37.5 mg
three times daily; digoxin, .125 mg each day; and furosemide, 120 mg
daily. The patient currently is clinically stable.
Discussion
DR. VICTOR J. DZAU (Chief, Division of Vascular Medicine
and Atherosclerosis, Brigham and Women's Hospital, and
Harvard Medical School, Boston, Massachusetts): This case
provides a good illustration of the central role of the kidney in
the pathogenesis and clinical management of congestive heart
failure. The patient had bilateral renal artery stenosis and
ischemic cardiomyopathy. Renal hypoperfusion as a result of
anatomic as well as functional abnormalities rendered this
patient particularly refractory to conventional therapy with
diuretics and digitalis. The use of captopril was complicated by
the development of acute renal insufficiency. We and others
previously have reported that captopril can produce acute renal
insufficiency in patients with bilateral renal arterial stenosis and
in those with unilateral arterial stenosis in a solitary functioning
kidney [I, 2]. This process can explain the rise in serum
creatinine in response to captopril in this patient. The mecha-
nism of captopril-induced renal insufficiency in patients with
bilateral renal arterial stenosis is complex. In this setting,
angiotensin II constricts the renal efferent arterioles, thus
maintaining glomerular filtration rate and filtration fraction.
Converting enzyme inhibitors can cause efferent arteriolar
dilation and simultaneous reduced renal perfusion pressure
[1—3]. These renal hemodynamic alterations can lead to reduced
glomerular filtration rate and an increased serum creatinine
level. The diagnosis of renal vascular hypertension should have
been entertained in this patient prior to this admission. He
developed hypertension after age 60, which was first noted 4
years prior to admission, and which was associated with a
serum creatinine of 1.8 mg/dl. The refractoriness of the hyper-
tension to control by methyldopa and hydralazine as well as the
increase in serum creatinine over the ensuing years are further
clues. Interestingly, over the year prior to admission, the
patient became normotensive coincident with a progressive
deterioration of cardiac function. Finally, the worsening in
renal function following captopril therapy provided the most
important clue to this diagnosis. The dramatic diuresis seen
after angioplasty in this patient demonstrates the critical impor-
tance of renal perfusion to the therapeutic renal response in
congestive heart failure [4].
The cardiorenal interaction in congestive heart failure is
complex. In addition to the contribution of primary renal
dysfunction to worsening cardiac failure in a patient with
already compromised cardiac function, secondary functional
changes in the kidney also occur as a direct result of cardiac
failure. These functional changes contribute to the pathophys-
iology of congestive heart failure. This subject has been previ-
ously reviewed by several investigators. My goal in today's
presentation is to provide an update on the current understand-
ing of the neurohormonal and renal mechanisms in cardiac
failure, and to review the therapeutic modalities, especially
converting enzyme inhibition, relating to the renal function and
natural history of patients with advanced cardiac failure.
Myocardial failure activates a series of compensatory mech-
anisms for maintaining cardiovascular homeostasis. These com-
pensatory mechanisms increase vascular tone and promote
sodium retention [5, 6]. Increased systemic vascular resistance
maintains systemic blood pressure in the presence of a declining
cardiac output. Similarly, increased sodium and water retention
increases plasma volume and ventricular filling pressure, and
theoretically should augment stroke volume. Excessive and
intense systemic vasoconstriction, however, imposes an in-
creased "afterload" on the failing heart and impedes left
ventricular ejection. Markedly expanded plasma volume can
result in transudation of fluid from the capillaries and can lead
to edema. Thus the renal and circulatory responses to the
diminished cardiac output play central roles in the pathophys-
iology of congestive heart failure.
Renal hemodynamics in cardiac failure
The renal adaptive responses to cardiac dysfunction can
occur extremely early in cardiac failure. Hostetter and cowork-
ers studied renal function in rats after experimental myocardial
infarction induced by coronary artery ligation [7]. Rats with
small to moderate-sized myocardial infarctions, despite main-
tenance of normal arterial pressure and "peak" pumping ability
of the left ventricle, exhibited a distinct impairment in their
ability to excrete sodium in response to an acute sodium load.
Both absolute and fractional sodium excretion were impaired.
This impairment in sodium handling occurred despite only mild
reductions in effective renal plasma flow (ERPF) and glomeru-
lar filtration rate (GFR), and in the absence of overt cardiac
failure. In rats with large infarctions, ERPF and GFR were both
reduced, and urinary sodium excretion in response to acute
sodium chloride loading was significantly attenuated. The intra-
renal hemodynamic changes in response to experimental myo-
cardial infarction and ventricular dysfunction were examined
further by Ichikawa and coworkers. They observed that
glomerular plasma flow rate (QA) was markedly impaired, while
the reduction in single-nephron glomerular filtration rate
(SNGFR) was proportionally less, and that these changes
resulted in an increase in single-nephron filtration fraction
(SNFF) [8]. Measurement of preglomerular, glomerular, and
postglomerular pressures and flows revealed that the reduction
in QA and the increase in SNFF were due to intense constriction
of the efferent arterioles. The increased resistance in the
efferent arterioles promoted the maintenance of glomerular
capillary hydraulic pressure and thus prevented a more marked
fall in GFR. These alterations in glomerular hemodynamics
might contribute to the increase in sodium retention in cardiac
failure via a decrease in peritubular hydraulic pressure and an
increase in peritubular oncotic pressure, thereby resulting in
increased proximal tubular fluid reabsorption [6]. In addition,
neurohormonal mechanisms may also affect tubular sodium
reabsorption in cardiac failure. DiBona and colleagues reported
that increased renal sympathetic nerve activity directly stimu-
lates proximal tubular sodium reabsorption [9, 10]. Angiotensin
II, aldosterone, and vasopressin all affect renal tubular sodium
handling [6]. I would now like to turn to an in-depth analysis of
these important neurohormonal mechanisms that influence re-
nal and electrolyte status in cardiac failure.
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Table 1. Neurohormonal systems in cardiac failure
1. Vasoconstricting-sodium retentive systems
Renin-angiotensin-aldosterone system
Sympathetic nervous system
Vasopressin
2. Vasodilating natriuretic systems
Prostaglandins (PGE2, P012)
Dopamine
Atrial natriuretic factor
Neurohormonal mechanisms in cardiac failure
The neurohormonal mechanisms activated in cardiac failure
include the sympathetic nervous system, the renin-angiotensin
system, vasopressin, prostaglandins, and atrial natriuretic fac-
tor [5, 11—14]. Each of these systems or hormones influences
systemic and renal vascular resistances and the renal handling
of sodium and water (Table 1). These neurohormonal systems
can be divided into two general classes: those that induce
vasoconstriction and promote sodium retention, and those that
stimulate vasodilation and induce natriuresis. The latter class of
hormones offsets or balances ("counter-regulates") the former
class. The sympathetic nervous and renin-angiotensin systems
and vasopressin belong to the first class, whereas prostaglan-
dins, atrial natriuretic factor, and dopamine belong to the
second class of hormones.
Vasoconstrictive-sodium retentive hormones in cardiac fail-
ure. My colleagues and I have studied the roles of the sympa-
thetic nervous system and the renin-angiotensin system in the
pathogenesis of experimental cardiac failure [15]. Acute exper-
imental cardiac decompensation is associated with activation of
the renin-angiotensin system and the sympathetic nervous
system, as well as stimulation of vasopressin release. These
systems maintain systemic blood pressure and promote renal
sodium and water retention during acute decompensation. In
the chronic "compensated" phase of experimental cardiac
failure, which is associated with expansion of extracellular fluid
volume and restoration of blood pressure, the plasma levels of
the hormones generally return to normal [16]. Similar patterns
have been reported in human cardiac failure [17]. Patients with
acute, poorly compensated, severe cardiac failure have mark-
edly elevated plasma renin activity, plasma norepinephrine,
vasopressin levels, and urinary catecholamines [181. In con-
trast, patients with chronic, stable cardiac failure have normal
plasma levels of these same hormones. Confirmation of the
importance of the clinical state in determining plasma neuro-
hormonal levels arises from sequential measurements in pa-
tients followed from acute cardiac decompensation to the
chronic stable stage. Both plasma renin activity and angiotensin
II levels were elevated during the former but returned to normal
during the latter stage [17]. Thus severe cardiac failure, either
progressing relentlessly or suddenly aggravated, is associated
with marked activation of the renin-angiotensin and sympa-
thetic nervous systems, which then deactivate and return to
normal as cardiac function stabilizes and circulatory compen-
sation occurs.
Many patients with cardiac failure exhibit hyponatremia [19].
Serum sodium concentration has been shown to be a useful
INal 135 [Nal > 135 10 (Nal 135 [Nal > 135
Fig. 1. Plasma norepinephrine, epinephrine, dopamine, and cortisol
concentrations in CHF patients with hyponatremia (serum Na  135
mEq/liter) and norinonatremia (serum Na > 135 mEq/liter). All hor-
mones were significantly higher in the hyponatremic patients (P < .01).
predictor of the state of the renin-angiotensin and sympathetic
nervous systems in cardiac failure. Indeed, an inverse correla-
tion has been reported between serum sodium concentration
and plasma renin activity [19—21]. When patients with conges-
tive heart failure were divided according to their serum sodium
concentration, hyponatremic patients (serum sodium concen-
tration <135 mM) had significantly higher levels of plasma renin
activity, angiotensin 11, and aldosterone than did normonatre-
mic patients [22]. Concentrations of other vasoactive hor-
mones, including norepinephrine, epinephrine, cortisol, dopa-
mine, and vasopressin, also were increased (Fig. 1). In contrast,
normonatrernic CHF patients had normal or nearly normal
plasma levels of these hormones. The current evidence thus
suggests that individuals with cardiac failure and hyponatremia
form a specific subgroup of patients characterized by clinical
decompensation and elevated levels of "stress" hormones.
These patients also have higher serum creatinine and blood urea
nitrogen concentrations because of prerenal azotemia [15, 22,
23]. Finally, they have a reduced ability to respond to circula-
tory alterations such as orthostasis [24], even though their
ventricular function may be similar to that in the clinically
compensated patient with a normal serum sodium concentra-
tion.
Several possible explanations exist for the relationship be-
tween hyponatremia and elevated vasoconstricting-sodium
retentive hormones. During cardiac decompensation these hor-
mones are activated for cardiovascular homeostasis. Angioten-
sin and vasopressin as well as the sympathetic nervous system
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all influence sodium and water clearance [5]. Furthermore,
angiotensin can induce vasopressin release, and angiotensin
may directly stimulate thirst [25]. Stimulation of thirst com-
bined with the antidiuretic effect of vasopressin and the reduc-
tion of free-water clearance resulting from increased proximal
tubular reabsorption of sodium can produce hyponatremia.
Hyponatremia might further stimulate increased plasma renin
activity [261. Thus, a vicious cycle may be set up under these
circumstances. I will return to a discussion of the mechanisms
of hyponatremia later.
Endogenous vasodilating-natriuretic hormones in cardiac
failure. Circulatory homeostasis is maintained by a balance
between vasoconstrictor and vasodilator mechanisms [19, 27].
Like the control of vascular tone, renal sodium excretion also is
controlled by a balance between opposing forces. Several
endogenous local and circulating hormonal substances with
natriuretic and vasodilatory properties have been reported.
These hormones include dopamine, prostaglandin E2, and atrial
natriuretic factor [12, 14]. Evidence suggests that these hor-
mones are counterregulatory forces to the vasoconstricting-
sodium retentive forces. Indeed, studies in patients with con-
gestive heart failure demonstrate a direct linear relationship
between the magnitude of systemic vasoconstrictive forces (as
reflected by plasma renin activity and angiotensin II concentra-
tion) and the magnitude of systemic vasodilator forces (as
measured by circulating levels of prostaglandin E2 and 12
metabolites) [19] (Fig. 2). The close correlation between circu-
lating levels of prostaglandin metabolites and angiotensin II in
patients with cardiac failure might reflect stimulation of
prostaglandin synthesis by angiotensin II, increased release of
renin induced by prostaglandin, or, most likely, a common
stimulus to both systems. Furthermore, a significant and strik-
ing inverse correlation is observed between serum sodium
concentration and plasma PGE2 metabolite concentration [19].
Indeed, hyponatremic patients have elevated plasma PGE2
metabolite concentrations and increased 6 keto PGFia and
dopamine levels [22]. Recently we observed that plasma atrial
natriuretic factor is also elevated in hyponatremic patients with
congestive heart failure as compared with normonatremic CHF
patients. The close correlation between the vasoconstrictor
forces (for example, angiotensin) and the vasodilator forces
(such as prostaglandin) suggests that these substances modulate
vascular tone. To further examine this possibility, we studied
the hemodynamic effects of indomethacin, a prostaglandin
synthetase inhibitor, in patients with cardiac failure [19]. When
given indomethacin, hyponatremic patients with elevated
vasodilating and vasoconstricting hormones had a significantly
decreased cardiac index as well as increased pulmonary capil-
lary wedge pressure, mean arterial pressure, and systemic
vascular resistance. In contrast, normonatremic patients with
normal concentrations of catecholamines, plasma renin activ-
ity, and prostaglandin E2 metabolites exhibited no significant
hemodynamic changes after administration of indomethacin.
Administration of the widely used antiinflammatory agents to
patients with severe cardiac failure may greatly alter this
delicate balance between opposing vasodilating and vasocon-
stncting forces [28]. Many vasodilatory drugs currently in use
in the treatment of cardiac failure might exert their effect, in
part, by increasing endogenous production of prostaglandins 12
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and E2. These effects may be attenuated by the administration
of drugs that inhibit the production of vasodilatory prostaglan-
dins (by blocking cyclooxygenase) [12]. Finally, nonsteroidal
antiinflammatory drugs also might induce intense renal vaso-
constriction by blocking renal prostaglandin production [29],
and perhaps precipitate acute renal failure [22, 30]. Our data
suggest that patients with hyponatremia are most likely to be
affected, favorably or adversely, by an alteration in this delicate
hormonal balance.
Two other potential natriuretic factors should be considered
in cardiac failure: dopamine and atrial natriuretic factor (ANF).
Dopamine induces natriuresis and increases renal plasma flow
and glomerular filtration rate. Two kinds of dopamine receptors
(DA! and DA2) have been identified in physiologic preparations
[31, 32]. Located postsynaptically, DA1 receptors mediate
vasodilation in coronary, renal, cerebral, and mesenteric blood
vessels. In contrast, DA2 receptors are situated on autonomic
ganglia and postganglionic sympathetic nerves. When DA2
receptors are stimulated, norepinephrine release from sympa-
thetic nerve terminals is inhibited. Theoretically, activation of
either DA1 or DA2 receptors in cardiac failure, endogenously
or pharmacologically, could induce natriuresis. In the case of
the DA1 receptor, natriuresis would be due to direct effects on
renal hemodynamics or direct inhibition of tubular sodium
reabsorption. With DA2 stimulation, natriuresis might result
from inhibition of norepinephrine release, thus depriving the
kidney of the antinatriuretic effects of sympathetic stimulation.
Goldberg and Raifer have proposed that dopaminergic nerves
exist in the kidney, and that dopamine is released locally to
influence renal sodium excretion [31]. This hypothesis is sup-
ported by reports that urinary excretion of dopamine increases
selectively with sodium loading in humans, and is correlated
positively with natriuresis [31].
Little is known about the status of endogenous dopamine in
cardiac failure. Circulating plasma levels of dopamine report-
edly are increased in patients with congestive heart failure [33],
and this increase is probably due to increased adrenal secretion
of this catecholamine. Myocardial stores in animals and humans
are increased relative to tissue stores of norepinephrine [34, 35],
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Fig. 2. Relationship of plasma PGE2 metabolite concentration to
plasma renin activity and plasma angiotensin concentration in patients
with CHF. (From Ref. 19.)
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Fig. 3. Contribution of atrial natriuretic factor to blood volume regu-
lation. Inhibitory signals are indicated by dashed lines, stimulatory
signals by solid lines. Increased blood volume stimulates the release of
atrial natriuretic factor and results in sodium and water excretion and
vasorelaxation. Atrial natriuretic factor also affects blood pressure and
sodium and water homeostasis by inhibiting the secretion of renin,
aldosterone, and vasopressin.
probably because the failing heart cannot hydroxylate dopa-
mine to norepinephrine [35]. The status of renal dopamine
metabolism in cardiac failure has not been studied. Thus it is
not known whether renal dopamine synthesis and its urinary
excretion are increased or decreased. The kidney, however,
remains responsive to infusions of exogenous dopamine despite
cardiac failure. When given to patients with severe CHF,
dopamine can increase renal blood flow out of proportion to the
increase in cardiac index. This response suggests a selective
renal vasodilatory effect [36]. Similar treatment with low doses
of dopamine has been reported to initiate a diuresis in patients
refractory to furosemide [37j. Moreover, oral dopaminergic
therapy with levodopa [38], ibopamine [39], the DA2 agonist
bromocryptine [40], and the DAI agonist fenoldopam [41] has
resulted in beneficial systemic hemodynamic effects in patients
with cardiac failure. The increase in renal blood flow and
natriuresis that results from DA1 receptor activation suggests a
selective renal vasodilatory effect [42]. These studies indicate a
therapeutic role for pharmacologic stimulation of renal DA1 and
DA2 receptors with the neurohormone dopamine or a related
agent in cardiac failure. The application of dopaminergic ther-
apy to cardiac failure clearly merits further prospective study if
this endogenous vasodilating system is to be used to greatest
advantage.
A novel and probably important natriuretic hormone exists in
granules in the mammalian cardiac atria. This hormone, atrial
natriuretic factor (ANF), possesses potent vasodilatory and
natriuretic properties. A detailed description of the properties
of ANF is available in several reviews [43—47]. Briefly, ANF
occurs naturally in human plasma, predominantly as a 28-
amino acid peptide that contains a 17-amino acid ring held
together by a disulfide bridge. The hormone is released in
response to atrial stretch, volume loading, or both. The molec-
ular form of ANF released by the atrium is reported to be
pro-ANF (a 126-amino acid peptide) [48]. The circulating form,
however, appears to be the 28-amino acid peptide. The hor-
mone does not exhibit Na-K ATPase inhibitory activity and
shows no cross-reactivity with digoxin antibodies. Receptors to
ANF have been localized in many tissues, including blood
vessels and the adrenal capsule [49].
The study of ANF seems particularly relevant to cardiac
failure. Atrial natriuretic factor in pharmacologic experiments
inhibits renin and aldosterone secretion as well as vasopressin
production [50], and blocks vasoconstrictor-augmented vascu-
lar contractility [51] (Fig. 3). When ANF is infused into animals,
blood pressure falls, whereas glomerular filtration rate and
filtration fraction increase and natnuresis ensues [52]. Thus
ANF has the characteristics of an ideal counterregulatory
natriuretic hormone in congestive heart failure, as it offsets the
sodium-retaining potential of the renin-aldosterone system.
We know that acute atrial stretch stimulates ANF release.
The critical question is whether ANF release also is stimulated
during chronic atrial hypertension associated with congestive
heart failure. Measurements of plasma ANF levels in human
cardiac failure reveal that the levels are elevated [53]. Whether
these elevated plasma ANF levels in chronic cardiac failure are
the same or are attenuated, as compared with the response to
comparable acute increases in atrial pressure, is not known.
Altered sensitivity to stretch might occur with chronic atrial
hypertension, leaving a blunted increase in plasma ANF levels
that are insufficient to overcome the sodium retentive forces.
Although studies in humans do not support a primary ANF
defect in congestive heart failure, Chimosky and colleagues
proposed that Syrian hamsters with congenital myopathic heart
failure are deficient in ANF [54]. This group reported that the
atrial ANF content is significantly reduced in these hamsters.
Symbiosis of normal hamsters with their myopathic kin pre-
vents development of fluid accumulation without altering the
progression of the cardiac degeneration. These findings suggest
that a primary defect in ANF synthesis contributes to increased
sodium retention in this model of cardiac failure. However,
other studies measuring plasma ANF levels disputed this pro-
posal by demonstrating that the plasma levels are increased in
these animals [55]. Further studies are necessary to elucidate
the role of ANF in cardiac failure. The question remains, are
elevations of plasma ANF in humans biologically significant?
Are pharmacologic doses of ANF necessary to show a renal,
endocrine, or vascular response to cardiac failure?
Scriven and Burnett administered synthetic ANF intrarenally
to control dogs and dogs with experimental cardiac failure [56].
The natriuresis and increased glomerular filtration rate induced
by ANF was blunted in the group with cardiac failure, demon-
strating a decreased responsiveness to ANF in this condition.
In humans with cardiac failure, such hyporesponsiveness may
also be seen. Cody et al infused synthetic ANF in CHF patients
and failed to observe a natriuresis despite a documented hemo-
dynamic response [57]. Hyporesponsiveness in ANF release in
response to acute stimuli also might exist in CHF. For example,
oral water loading plus water immersion to the neck fails to
correct the salt and water retention of the kidney in cardiac
failure [58]. Our preliminary data suggest that water immersion
failed to increase further the plasma ANF level in these patients
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(unpublished observations). The theme of decreased respon-
siveness to volume regulatory signals is also supported by the
data of Zucker and coworkers, who demonstrated impaired left
atrial responsiveness to stretch in dogs with chronic, high-
output congestive heart failure [59]. It may well be that altered
stretch or barosensitivity occurs with chronic exposure to a
high-pressure, high-volume circulation, keeping plasma ANF
levels tonically elevated but insufficient to overcome depressed
end-organ responsiveness or tachyphylaxis.
The ability of ANF to cause vasodilation, induce natriuresis,
and block vasoconstricting-sodium retentive hormone secretion
makes it an ideal agent for the treatment of human heart failure,
at least theoretically. Riegger and colleagues studied the effect
of infusions of ANF in 7 patients with severe congestive heart
failure [60]. Dose-dependent increases in cardiac output, a fall
in pulmonary arterial and systemic pressures, and suppression
of plasma aldosterone and cortisol were observed. Both natri-
uresis and kaliuresis occurred. As mentioned earlier, other
investigators also have administered ANF infusions to patients
with cardiac failure and have observed mixed responses [601. In
some patients, ANF failed to induce natnuresis or diuresis ([57,
60]; Nicholls MG, Espiner E, personal communication).
It thus appears that circulating plasma ANF is increased in
cardiac failure in response to the increase in blood volume.
Although a variable response to pharmacologic doses of ANF
occurs, the significance of physiologic changes in plasma ANF
concentrations remains to be determined. Endogenous ANF
likely will be shown to modulate natriuresis through at least a
permissive action. Pharmacologically, ANF might prove useful
in the therapy of congestive heart failure.
In summary, evidence suggests that a variety of endogenous
natriuretic and vasodilatory substances—notably atrial natri-
uretic factor, dopamine, and prostaglandins—may play a col-
lective, interdependent role in offsetting the sodium-retentive
neurohormonal storm characteristic of congestive heart failure.
Therapeutic advances in the treatment of cardiac failure may
derive from avoidance of disruption of these natriuretic hor-
monal responses, from enhancement of these endogenous fac-
tors, or from pharmacologic administration of endogenous
substances like ANF or their analogues. Future research on the
body's natural defenses against volume overload in cardiac
failure should provide new insights into pathophysiology and
therapy.
Cardiorenal interactions in cardiac failure
To achieve an understanding of the pathophysiology of
cardiac failure, we first must examine the relationship of cardiac
sensors and volume regulation. Stimulation of atrial or ventric-
ular receptors by stretch or volume expansion results in with-
drawal of renal sympathetic outflow and inhibition of renin and
vasopressin release (Fig. 4) [61—64]. In addition, studies of
total-body water immersion as well as sodium loading in hu-
mans have demonstrated increased urinary prostaglandin PGE2
and dopamine excretion [31, 65], suggesting increased renal
production of these natriuretic substances. Atrial natriuretic
peptide also appears to be released in response to water
immersion.
Patients with congestive heart failure have abnormalities in
cardiopulmonary baroreflex function and hormonal secretion
Fig. 4. Overview of cardiovascular regulation of renal function. Inhib-
itory signals to each organ are indicated by dashed lines, stimulatory
signals are indicated by solid lines. Increases in blood volume stimulate
cardiopulmonary baroreceptors and secretion of ANF. Increases in
systemic arterial pressure stimulate arterial baroreceptors. Barorecep-
tor activation sends inhibitory signals to the central nervous system
vasomotor center, and cause suppression of sympathetic efferent activ-
ity and increased vagal efferent activity (not shown).
[66]. In a dog model of cardiac failure, atrial receptors with
myelinated afferent vagal fibers have a decreased response to
elevations of atrial pressure. Both threshold and sensitivity to
pressure changes are attenuated [65, 67]. The sensitivity of
atrial receptors improves following reversal of experimental
cardiac failure [68]. In chronic cardiac failure, despite persistent
elevation of atrial and ventricular pressures, plasma renin and
vasopressin are not suppressed. These data suggest that an
alteration in cardiopulmonary control of sodium-retentive hor-
mones may exist in cardiac failure. Altered cardiopulmonary
baroreceptor function in cardiac failure may be secondary to
decreased myocardial compliance or to structural changes
within the baroreceptors. In addition, cardiac baroreceptors
may be diminished by decreased contractile states. Arterial
baroreceptor activities have been demonstrated in animal mod-
els of heart failure. Reductions in baroreflex sensitivity and/or
increases in threshold reduce the reflex inhibition of sympa-
thetic efferent activity. Thus, circulating levels of catechola-
mines, renin, and vasopressin may increase. As a result,
activation of these neurohormonal systems may cause renal
vasoconstriction and can contribute to sodium and water reten-
tion. The heart rate as well as systemic and regional vasocon-
strictor responses to lower-body negative pressure or postural
tilt are depressed or absent in patients with heart failure [69—72].
Furthermore, the increase in plasma catecholamines, plasma
renin activity, and plasma vasopressin concentrations usually
observed in normal subjects with orthostasis are impaired in
patients with cardiac failure. The response of the endogenous
vasodilating natriuretic hormones to changes in loading condi-
tions of the cardiopulmonary receptors have not been well
studied. The failure of head-out, total-body water immersion to
induce natriuresis and diuresis in patients with chronic heart
Blood
volume
Sodiumand
water excretion
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Table 2. Effect of vasodilators on renal blood blow
Vasodilator Renal blood flow
ACE inhibitor Increase (selective)
Hyralazine Increase (nonselective)
Calcium channel blockers Increase (nonselective)
Prazosin No effect
Nitrates No effect
failure [57] suggests that the responses of ANF, PGE2, and
dopamine may be attenuated, or at least are insufficient to
overcome the sodium retentive forces. Indeed, our preliminary
data suggest that plasma ANF did not increase further during
water immersion (unpublished data).
Renal response to vasodilatory drugs in
cardiac failure
As our understanding of the role of these neural and hor-
monal factors in cardiac failure has increased, development of
more rational therapy has become possible. The last decade has
seen the application of specific pharmacologic antagonists in the
use of vasodilators in the management of congestive heart
failure [101. Angiotensin-converting enzyme inhibitors, which
inhibit the production of angiotensin II, have become the gold
standard of vasodilator therapy for congestive heart failure [23,
731. Phentolamine and prazosin (alpha-adrenoreceptor antago-
nists) have been used to block vascular and renal effects of
increased sympathetic nervous system activity. Nonselective
vasodilators such as nitrates, hydralazine, and calcium antago-
nists also have been used for the treatment of patients with
congestive heart failure. A critical determinant of the efficacy of
vasodilators in the treatment of cardiac failure is the renal
response to the vasodilator agent. Agents that increase renal
blood flow and GFR should promote sodium excretion and
enhance the effect of diuretics. Table 2 summarizes the effects
of various vasodilators on renal blood flow. Angiotensin-con-
verting enzyme inhibitors selectively increase renal blood flow
in preference to other regional circulations [15, 22, 74]. Hydral-
azine and calcium antagonists increase renal blood flow
nonselectively; that is, the increment of renal blood flow is
directly proportional to the increase in cardiac output. Prazosin
and nitrates have no effect on renal blood flow. The dominant
role of the renin-angiotensin system in the pathogenesis of
azotemia and sodium retention in congestive heart failure was
suggested by the experimental studies of Ichikawa and cowork-
ers [8]. Administration of angiotensin-converting enzyme inhib-
itor in rats with congestive heart failure resulted in an increase
in QA, SNGFR, and a reduction in SNFF. These findings can
best be explained by the demonstration that efferent arteriolar
resistance fell substantially in response to the blockade of
angiotensin II production (Fig. 5). Furthermore, the glomerular
capillary ultrafiltration coefficient (Kf) rose significantly. The
contribution of the renin-angiotensin system to renal dysfunc-
tion in patients with congestive heart failure is supported by
reports that a significant correlation exists between serum
creatinine and plasma renin activity [17, 75]. Patients with
hyponatremia and elevated plasma renin activity have signifi-
Fig. 5. Effect of ACE inhibition on renal function of rat and man.
Changes in single-nephron filtration fraction (SNFF), single-nephron
GFR (SNGFR), glomerular plasma flow rate (Q3, mean glomerular
capillary hydraulic pressure (PGC), afferent (RA) and efferent (RE)
arteriolar resistance, and glomerular capillary ultrafiltration coefficent
(Kf) in response to teprotide administration. Values are expressed as
the mean percentage of changes from initial control levels. Hatched
bars denote rats with myocardial infarction, open bars sham-operated
control rats. The asterisk indicates a significant difference, with P <
0.05. (From Ref. 4.)
cantly higher BUN and plasma creatinine concentrations and
lower renal blood flow and glomerular filtration rates [22].
Angiotensin-converting enzyme (ACE) inhibitor therapy may
improve renal function in patients with severe cardiac failure
and reduce the requirement for diuretic agents [15, 22, 74].
Furthermore, hyponatremia may revert to normal with the
addition of an ACE inhibitor to the medical regimen [74, 76].
The renal effects of ACE inhibition in patients with cardiac
failure have been debated. One can reasonably expect that ACE
inhibition will improve or produce no effect on renal function in
patients with mild to moderate cardiac impairment in whom the
cardiac functional capacity is sufficient to sustain a significant
increase in cardiac output necessary to maintain blood pressure
and renal perfusion in the presence of systemic vasodilation.
The renal response to ACE inhibition in patients with severe
CHF is more complex, however. Pierpont and associates re-
ported an increase in BUN and serum creatinine in 3 of 9
patients after 3 days of captopril therapy [77]. Faxon and
colleagues saw an improvement in renal plasma flow without a
change in the GFR after a single dose of captopril [78], whereas
Mujais and colleagues reported that captopril reduced both
renal plasma flow and GFR [79]. In contrast, studies with
prolonged captopril administration have shown sustained im-
provement of both renal plasma flow and GFR [23, 74]. The
+10 01
01 _10IrU- I I2 I I
_20[
—201. —30
+4Ør +90
+20L
+60
I
-'-30•U- I RE2 I
Ca') I
-401. *
+801
+2001-
a<+20 I+100 r
0 I
Ua
'0.
A4
Renal and circulatory mechanisms in CHF 1409
0
E
2
C',
o Group I
'Group II
000
0 0
Serum sodium Concentration
(mEq/L) before captopril
apparent discrepancies might be due to differences in study
design. For example, in studies of captopril's short-term ef-
fects, a single captopril dose was not titrated to blood pressure
or to the hemodynamic response [78, 79]; furthermore, diuretic
agents were withheld in these studies. On the other hand, in
studies in which captopril doses were titrated and the GFR and
renal plasma flow were studied during chronic therapy, sus-
tained improvement of renal plasma flow and GFR were re-
ported [23, 74, 80]. As Pierpont and associates showed, the
initial deterioration of renal function with acute captopril ad-
ministration might be related to an excessive decrease in renal
perfusion pressure, complicated by blockade of angiotensin-
mediated autoregulation of GFR [77]. The mean blood pressure
of these patients with severe congestive heart failure is often
very near the autoregulatory break point. Thus, a further fall in
blood pressure can result in a substantial decrease in renal
plasma flow and GFR.
Chronic captopril therapy with dosage adjustments, as in our
studies, can avoid an excessive and precipitous reduction in
renal perfusion pressure and can optimize renal hemodynamic
changes. Indeed, in our experience [23, 74], GFR increased by
38% and renal plasma flow by 48% after one week of captopril
therapy. Recently Packer and coworkers compared the effect of
two different angiotensin-converting enzyme inhibitors on renal
function in patients with cardiac failure and reported that
enalapril therapy increased serum creatinine and plasma potas-
sium and reduced creatinine clearance [81]. In contrast,
captopnl improved creatinine clearance and reduced body
weight, but it had no effect on serum creatinine or plasma
potassium. These discrepant renal effects can be explained by
the duration of actions of these two drugs. Enalapril, which has
a prolonged duration of action, may produce sustained renal
hypotension in contrast to the effect of captopril, and thus
causes a net reduction in creatinine clearance.
We examined whether an ACE inhibitor alone (without
diuretics) has a significant diuretic effect in patients with
congestive heart failure or whether furosemide is needed for
this response [74]. We studied 14 patients receiving a diet
containing 40 mEq of sodium daily. Significant weight loss did
not occur despite the improved renal plasma flow and GFR in
patients treated with captopril alone for 5 days. However, when
captopril was given with furosemide, body weight and edema
were both reduced significantly. Furthermore, the diuresis and
natriuresis were achieved without inducing azotemia and with a
modest dose of the diuretic agent (40 to 80 mg/day). In our
experience, the renal effects of ACE inhibitors seemed to reflect
primarily an enhancement of the renal response to furosemide.
Another area of debate concerns the ACE inhibitor's effect
on hyponatremia in patients with cardiac failure. We have
reported that hyponatremia was corrected with the addition of
captopril to the medical regimen [23, 74]. Pierpont and associ-
ates [77] and Maslowski and colleagues [82], on the other hand,
reported that serum sodium concentration decreased after 3 and
6 days of captopril therapy. However, the protocol used by
these authors, in which diuretic agents were withheld when
captopril was administered, differed from that in our study. Our
data show that captopril itself has little effect on serum sodium
concentration. Captopril and furosemide in combination, how-
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Fig. 6. A Comparison of serum sodium concentration in two groups of
hypernatremic patients with CHF. After a control period with captopril
or furosemide (period 1), the first group of patients received furosemide
(period 2) and then captopril plus fusosemide (period 3). The second
group did not receive furosemide during period 2 and received captopril
alone during period 3. (Adapted from Ref. 74.) B Response of serum
sodium concentration of the same patients in the second group
(captopril alone, period 3) when furosemide was added to capt opril
(period 4). (Adapted, with permission, from: Dzau VJ, Mollenberg NK:
Renal response to captopril in severe heart failure. Ann Intern Med
100:777—782, 1984.)
ever, corrected hyponatremia in patients with severe cardiac
failure (Fig. 6).
The mechanism of hyponatremia in patients with severe
congestive heart failure is unclear and probably multifactorial,
as I alluded to earlier [83—86]. Decreased effective arterial
volume and renal perfusion in congestive heart failure can lead
to water retention due to (1) decreases in distal delivery of
sodium and filtrate resulting in impairment of free-water excre-
tion; (2) increased thirst or increased antidiuretic hormone
release in response to nonosmotic stimuli; and (3) a water-
excreting defect induced by diuretic agents. Our data show that
diuretic agents were not primarily responsible for hyponatremia
in those patients, because discontinuation of furosemide did not
affect serum sodium concentration [74]. Excessive water intake
was not principally responsible for hyponatremia in the patients
in this study because total fluid intake was similar to that in the
normonatremic patients. A contribution of antidiuretic hor-
mone to the hyponatremia cannot be excluded and is quite
likely the major cause of the observed water-excreting defect.
Enhanced proximal tubular reabsorption of sodium occurs
with edema. More than 20 years ago, Cirksena, Dirks, and
Berliner demonstrated enhanced proximal tubular reabsorption
of sodium by performing micropuncture studies in dogs with
caval constriction [87]. This conclusion is supported by evi-
dence based on clearance and micropuncture techniques in
dogs with cardiac failure due to an arteriovenous fistula [88].
These observations are supported by two lines of investigation
in humans. In patients with congestive heart failure, the natri-
uresis associated with distal tubular blockade induced by di-
uretic agents led to the conclusion that proximal tubular reab-
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sorption was increased [89]. In patients with congestive heart
failure or hepatic cirrhosis, moreover, administration of an
osmotic diuretic agent led to increased free-water clearance;
this observation could be accounted for only on the basis of
increased delivery of sodium from the proximal tubule to the
loop of Henle [90,91]. The loop of Henle may also contribute to
this sodium reabsorption. Haas and coworkers have shown that
this is the likeliest site of sodium reabsorption during mm-
eralocorticoid escape [92]. Because patients with congestive
heart failure usually have severe secondary aldosteronism,
sodium retention can be enhanced by the action of the mm-
eralocorticoid.
We have confirmed that in the presence of a stable perfusion
pressure, captopril can induce an increase in renal plasma flow
in patients with advanced congestive heart failure. The conse-
quent increase in peritubular capillary hydraulic pressure, ac-
companied with maintained or increased glomerular filtration
rate all would tend to lead to increased delivery of sodium to the
loop of Henle, the locus of furosemide's action, and in this way
would enhance the action of furosemide. Another possibility is
that the increased cortical blood flow could have led to in-
creased delivery of furosemide to the kidney and to its site of
action in the loop. Angiotensin converting enzyme inhibition
also blocks aldosterone production and thus might enhance the
natriuretic action and counteract the kaliuretic effect of furose-
mide. A more remote possibility is that the combination of ACE
inhibitors and furosemide leads to a more substantial improve-
ment in cardiac hemodynamics and pulmonary congestion, and
results in the suppression of plasma antidiuretic hormone levels
responsible for hyponatremia. Finally, Carvounis and col-
leagues showed that captopril decreased vasopressin-stimula-
ted water flow in the toad bladder [93]. Such a mechanism may
be operative, when combined with furosemide, in the correc-
tion of hyponatremia in patients with congestive heart failure.
In summary, ACE inhibition may improve renal plasma flow
and GFR in patients with congestive heart failure if sustained
hypotension is avoided. Significant diuresis and natriuresis can
be achieved without inducing azotemia by using a combination
of furosemide and captopril. Diuresis and correction of
hyponatremia occur in patients treated with captopril and
furosemide but not with captopril alone. Angiotensin-convert-
ing enzyme inhibition enhances the renal effect of furosemide.
On the basis of our study [74], we recommend titration of the
dose of the ACE inhibitor to minimize hypotension. We also
recommend the concurrent use of furosemide, especially for
those in whom azotemia and hyponatremia are present.
Neurohormonal levels and prognosis in clinical
cardiac failure
Despite advances in the understanding of the pathophysiol-
ogy of cardiac failure, the prognosis for patients with congestive
heart failure remains poor [94, 95]. Recent data demonstrated
that plasma hormonal levels and serum sodium concentration
can predict the survival of patients with congestive heart failure
[95, 96]. Cohn and coworkers reported that patients with
plasma norepinephrine levels greater than 800 pg/mI have a
significantly worse prognosis than do those with plasma norep-
inephrine levels of 400 to 800 pg/mI [95]. Patients whose plasma
norepinephrine levels are nearly normal, that is, less than 400
pg/mI, have relatively the best prognosis. Lee and Packer
observed that hyponatremic patients with CHF have a signifi-
cantly shorter survival time than do normonatremic patients
with cardiac failure (Fig. 7A) [96]. These independent observa-
tions are clearly related; a relationship has been described
between hyponatremia and elevated plasma vasoconstricting-
sodium retentive hormones in patients with poorly compen-
sated heart failure [19—21]. Lee and Packer reported further that
administration of an ACE inhibitor significantly improved the
survival of hyponatremic patients with CHF, whereas adminis-
tration of non-ACE inhibitor vasodilators did not influence the
prognosis of patients with hyponatremia (Fig. 7B) [96]. Thus,
blockade of the actions of vasoconstricting-sodium retentive
hormones might influence the course of cardiac failure. Re-
cently, the Veterans Administration Heart Failure Study re-
ported that the combination of hydralazine and isosorbide
nitrate reduced the cumulative mortality of CHF patients,
whereas prazosin had no effect [97]. Unfortunately this study
did not examine the effect of ACE inhibitors. One retrospective
analysis of all controlled studies involving vasodilator therapy,
including ACE inhibition, in cardiac failure reported that nei-
ther nitrates, prazosin, nor hydralazine alone had any impact on
mortality rates in patients with cardiac failure who were receiv-
ing digitalis and diuretics [98]. In contrast, patients receiving
ACE inhibitors had a significantly lower mortality rate than did
patients receiving a placebo. The beneficial effect of ACE
inhibition in cardiac failure might be due to the blockade of
angiotensin II, reduction in sympathetic activity, and activation
of endogenous prostaglandins [99]. These effects can reduce
both afterload and preload as well as improve renal function.
The failure of hydralazine or prazosin to improve survival might
be due to activation of neurohormonal mechanisms during the
chronic administration of these vasodilators [15]. Indeed, a
recent double-blind comparison of captopril and prazosin dem-
onstrated that prazosin treatment activated plasma norepineph-
rine and renin-angiotensin levels [100]. Chronic administration
of prazosin resulted in an increase in body weight and an
attenuation of vasodilatory effects over time. In contrast,
administration of an ACE inhibitor blocked angiotensin II
production, did not affect plasma norepinephrine levels, im-
proved renal function, and reduced body weight [100]. In a
similar study, Lilly and coworkers demonstrated that hydral-
azine markedly increased plasma norepinephrine levels,
whereas captopril did not [101]. Patients who were treated with
hydralazine had a higher mortality rate as compared with those
who received captopril. Increased plasma catecholamine may
predipose these patients to ventricular arrhythmias and sudden
death. On the other hand, ACE inhibitors have been shown to
reduce the frequency of ventricular arrhythmias in these pa-
tients [102]. Thus, neurohormonal compensatory activation
during vasodilator therapy may determine survival as well as
drug response.
In summary, circulatory and renal adaptive mechanisms are
activated during cardiac failure. These compensatory changes
contribute to the pathophysiology of the syndrome of cardiac
failure, form the rational basis for vasodilator therapy, deter-
mine long-term drug responsiveness, and probably influence
survival in these patients.
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Questions and answers
enzyme inhibition is not influenced directly by basal renal
function but by plasma renin activity. We and others have
reported that the magnitude of the decline in systemic blood
pressure and left ventricular filling pressure to converting
enzyme inhibition correlated inversely with serum sodium
concentration [19, 21]. In this context, an indirect relationship
exists between acute hemodynamic response and renal func-
tion; we observed that patients with elevated PRA and hypo-
natremia in general have elevated BUN and serum creatinine
levels.
DR. RONALD PERRONE (Division of Nephrology, New En-
gland Medical Center Hospitals): Can one generally predict
who does well or poorly when given a converting enzyme
inhibitor?
DR. DZAU: As I said earlier, the acute hemodynamic re-
sponse including symptomatic hypotension can be predicted by
the baseline serum sodium concentration [21]. Patients with
hyponatremia are more prone to develop symptomatic hypo-
tension in response to an ACE inhibitor than are normonatre-
mic patients. As a group, hyponatremic patients have poor
hemodynamic compensation, and ACE inhibition appears to
increase survival in these patients [96].
DR. PERRONE: Are the hyponatremia data obtained on ran-
dom patients with random salt and water intake, and are there
any rigorious studies of free-water clearance and balance?
DR. DZAU: A large part of our data is derived from metabolic
balance studies performed in the Clinical Research Center in
patients who are not taking diuretics [19, 23, 24, 74]. However,
the rest of our data [17] as well as the large experiences of other
investigators [20, 21] are based on patients with a random-
51) sodium diet and free access to water who are receiving diuret-
ics. Thus it appears that the relationship of hyponatremia and
plasma renin activity holds true regardless of the study condi-
tions.
DR. MICHAEL MADAIO (Division of Nephrology, New En-
gland Medical Center Hospitals): What is the explanation for
the increased systemic vascular resistance following indometh-
acm administration in patients with congestive heart failure and
hyponatremia?
DR. DZAU: Patients with hyponatremia have elevated plasma
levels of vasoconstrictive hormones such as angiotensin and
catecholamines. The effects of these hormones on the vascula-
ture are modulated by increased tissue production of vasodila-
tory prostaglandins. Indomethacin inhibits cyclooxygenase ac-
tivity and blocks the synthesis of prostaglandins 12 and E2. This
inhibitory action causes "unopposed" vasoconstriction.
DR. JORDAN I. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital and Medical Center, Chicago, Illi-
nois): In relation to the other mechanisms you described, how
important is the sympathetic innervation of the kidney in
congestive heart failure?
DR. DZAU: I think the role of the sympathetic nervous system
is well established. It is activated in "decompensated" patients
with congestive heart failure, and it contributes to vasoconstric-
tion and sodium retention.
DR. RICHARD KOPELMAN (Division of General Internal Med-
icine, New England Medical Center Hospitals): Does enalapril
also stimulate prostaglandin synthesis?
DR. DZAU: This is an area of some controversy. Given et al
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Fig. 7 A Kaplan-Meier analysis showing cumulative rates of survival
in patients with severe chronic heart failure stratified into two groups
based on pretreatment serum sodium concentration (> 137 versus 
137 mEq/liter). Hyponatremic patients fared significantly worse than
did patients with a normal serum sodium concentration (P =
.006,
Wilcoxon Breslow). B Kaplan-Meier analysis of cumulative rates of
survival in patients with cardiac failure and hyponatremia (pretreat-
ment serum sodium concentration 137 mEq/liter) strat(fled into two
groups based on treatment. Patients treated with converting-enzyme
inhibitors (CEL) had a significantly more favorable long-term prognosis
than did patients who received drugs that did not interfere with the
renin-angiotensin system (Non-CEL) (P = < .003, Wilcoxon-Breslow).
(From Ref. 97.)
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center Hospitals): Is the hemodynamic
and clinical response to converting enzyme inhibition related to
basal renal function in patients with congestive heart failure?
DR. DZAU: The acute hemodynamic response to converting
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reported that enalapril did not increase plasma PGE2 metabolite
levels in normal volunteers [103]. Zusman reported that
captopril but not enalapril produced an increase in PGE2
synthesis by cultured renal medullary interstitial cells [104].
However, Oparil and coworkers reported increased urinary
6-keto-PGF1 excretion in patients with low-renin, essential
hypertension who were treated with enalapril [105].
DR. MADIAS: You alluded to the discrepant renal effect of
captopril and enalapril in patients with cardiac failure [81]. Are
differences in the mechanism of action rather than in duration
more important? Is chronic treatment with captopril character-
ized by periodic escape from converting-enzyme inhibition?
DR. DZAU: This is an excellent question. Several mechanisms
might account for the differences in renal functional response to
captopril and enalapril: (1) differences between the two drugs in
the duration of blood pressure reduction and serum ACE
inhibition, (2) differences in renal prostaglandin production that
might influence renal hemodynamics, and (3) differences in the
profile of tissue ACE inhibition. Indeed, evidence suggests that
enalapril produces a more prolonged and complete inhibition of
renal and cardiac ACE than does captopril [1061.
DR. JOHN T. HARRINGTON (Chief, Department of Medicine,
Newton-Welles!ey Hospital, Newton, Massachusetts): Are
there experimental studies which show that captopril decreases
proximal tubular sodium reabsorption?
DR. DZAU: I am not aware of any.
DR. COHEN: Are the renin-aldosterone-angiotensin and
neurohormonal systems maladaptive in congestive heart fail-
ure?
DR. DZAU: The renin-angiotensin system is an adaptive
system that maintains cardiovascular homeostasis in organisms
with normal cardiac function during states of dehydration,
hemorrhage, and volume contraction [25]. In severe CHF, the
system is maladaptive. In severe heart failure, the neurohor-
monal systems are activated to support blood pressure. The
intense vasoconstriction can reduce regional blood flow, how-
ever. With the increase in systemic vascular resistance, the
impedance to ventricular ejection is also greatly increased and,
as a consequence, the forward output is decreased.
DR. COHEN: You appear to be describing a positive-feedback
system. Why doesn't the system fall apart when it gets into this
mode?
DR. DzAu: Indeed, the fundamental hypothesis in severe
cardiac failure is that it is a vicious cycle of impaired cardiac
output and increased vasoconstriction and that, if untreated,
there is ultimate cardiovascular collapse. In fact, the physio-
logic and pharmacologic basis of vasodilator therapy is the
elimination of this positive feedback.
DR. MADIAS: Recent data have provided evidence that acti-
vation of the vascular tissue renin-angiotensin system might
contribute to the increased vascular tone in chronic two-kidney,
one-clip hypertension [108]. Are there any similar data in
experimental models of congestive heart failure?
DR. DZAU: No, none of which I am aware.
DR. COHEN: The ultimate inhibitor of the renin-angiotensin
system is bilateral nephrectomy. Are there any data on the
response of the failing heart in patients who have no kidneys?
DR. DZAU: I know of no clinical or laboratory data on
bilateral nephrectomy in cardiac failure.
DR. GEETHA NARAYAN (Clinical Director, Tn-City Dialysis
Center, Medford, Massachusetts): In the presence of a stable
perfusion pressure, how does converting enzyme inhibition
increase glomerular ifitration rate in cardiac failure?
Du. DZAU: In advanced congestive heart failure, intense
angiotensin-mediated renal arterial, as well as afferent and
efferent arteriolar, constriction may be seen. Furthermore,
glomerular surface area also is reduced because of angiotensin-
mediated mesangial contraction. In the presence of a stable
perfusion pressure, angiotension converting enzyme inhibition
may, therefore, increase GFR via renal arterial and afferent
arteriolar dilation as well as via increased glomerular surface
area.
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